Cerevel Therapeutics Holdings Inc (CERE) Actualités

Form POS AM - Post-Effective amendments for registration statement

Form POS AM - Post-Effective amendments for registration statement

Form 8-K - Current report

AbbVie Completes Acquisition of Cerevel Therapeutics

AbbVie Completes Acquisition of Cerevel Therapeutics PR Newswire NORTH CHICAGO, Ill., Aug. 1, 2024 Cerevel's clinical-stage assets complement...

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Cerevel Therapeutics Announces Positive Topline Results for Tavapadon in Phase 3 Adjunctive Trial for People Living with Parkinson’s Disease

Tavapadon met the primary endpoint in the pivotal Phase 3 TEMPO-3 adjunctive trial, demonstrating a...

Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]

Form 8-K - Current report

Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material

Form 4 - Statement of changes in beneficial ownership of securities

Kuehn Law Encourages MDC, WAVD, NS and CERE Investors to Contact Law Firm

Kuehn Law Encourages MDC, WAVD, NS and CERE Investors to Contact Law Firm PR Newswire NEW YORK, Jan. 24, 2024...

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities